New Class of Mutations that Respond Well to Chemotherapy Identified in PNET Patients

We are pleased to share an exciting update on Dr. Diane Reidy’s project, “Personalized Medicine for Neuroendocrine Tumor Patients.” In particular, Dr. Reidy’s goals are to study patient tumor samples to develop biomarkers to predict patient response to targeted therapies. This will help classify pancreatic neuroendocrine tumor (pNET) patients for treatment with targeted therapies or chemotherapy. This project has been funded in part by NETRF’s Cycle for Survival Team. Since 2012, over $300,000 has been raised by Cycle for Survival to support this important work.

The project is still ongoing but has already made important advances. In particular, they have:

  • Identified a new class of mutations among patients with pNETs and observed correlation between these patients and a good response to chemotherapy.
  • Identified mutations among patients with pNETs similar to those found previously among patients with ileal carcinoid tumors that suggest a new treatment strategy. They plan to open a clinical trial to test this new treatment strategy in cooperation with other institutions in 2016.
  • Identified mutations in MEN1, Daxx and ATRX among patients with pNETs similar to those previously identified by other NETRF researchers among patients with pNETs.

They still have important work to do in order to accrue more patients to the study and to find more correlations between patient mutational status and response to therapies. Read more about Dr. Reidy’s work on the Cycle for Survival page.

We need your continued support of our Cycle for Survival team to keep this important work going.  Please consider signing up or joining today!

7
Leave a Reply

5 Comment threads
2 Thread replies
0 Followers
 
Most reacted comment
Hottest comment thread
6 Comment authors

This site uses Akismet to reduce spam. Learn how your comment data is processed.

  Subscribe  
newest oldest most voted
Notify of
stephen marx

We call this news release a “teaser”. Without naming the mutations and some features, it is impossible to understand its importance. The person who begins such a “teaser” has an abligation to support reasonable science with more information.

We will follow up this story as soon as we have more information, but wanted to let the community know about this exciting discovery. Thanks for reading!

Aaron Vinik

Would really like to hear about these novel mutations and determine if it is worthwhile examining tissues or samples from our patient population!

Sharon D Frank

I was diagnosed with P-NET in November, 2012. I have Mets to the liver, and was put on CAP-TEM in 2013/2014…13 rounds…and the liver Mets showed significant shrinkage. During the Summer of 2015, I entered a Phase 1 Trial, and was taken out of the trial after approximately two months later, as the Mets were showing significant growth, and am once again on CAP-TEM. I received an email containing this article, and, obviously, it caught my attention! I am very interested in receiving information on the studies and upcoming trials. Thank you so much for this very important work! Sincerely,… Read more »

Linda Silversmith

Chemotherapy is a vague term here – could you be more specific about the types of chemotherapy tried?

We hope to have more specifics about this discovery and will certainly update everyone with more details as soon as they are available to us. Thanks so much!

Mischelle Bowser

I would just be interested in knowing more about this type of cancer. Thank you

New Class of Mutations that Respond Well to Chemotherapy Identified in PNET Patients